Objective To review sperm cryopreservation usage rates, corresponding reproductive outcomes, and the current situation in our locality.
Introduction
The number of young men in the reproductive age bracket with cancers who survive has increased dramatically over the last few years, largely due to improvements in diagnostic and treatment modalities. [1] [2] [3] [4] Testicular cancer and Hodgkin's disease are the New knowledge added by this study • Sperm cryopreservation for male cancer patients is underutilised in the Hong Kong population.
• Approximately 85% of the referred patients had successful sperm cryopreservation, demonstrating the feasibility of this procedure. • In our study, up to 32% (n=11/34) of the patients had significantly worse semen analysis findings (including four who suffered from azoospermia) after their gonadotoxic treatment. Thus, sperm cryopreservation is an invaluable tool for preserving the progenitive potential of male patients undergoing gonadotoxic treatment.
Implications for clinical practice or policy
• Every effort should be made to refer these patients for sperm cryopreservation before proceeding to their gonadotoxic treatment, even if their sperm quality is suboptimal.
• Clinical policies are required to increase awareness about sperm cryopreservation knowledge in patients and physicians.
two most common malignancies among young males in this age-group. Advances in chemotherapy have greatly improved the cure and survival rates of these patients. The 5-year survival for testicular cancer is 95%, while for Hodgkin's disease it is up to 80%. [1] [2] [3] [4] [5] The majority of these cancer patients are diagnosed when they are still young, most being single and/or not having completed their families. In this group of patients, male infertility is therefore still a major concern, since the treatment necessary (chemotherapy or radiotherapy) may adversely affect their fertility. Although the harmful effects of chemotherapy or radiotherapy on spermatogenesis largely depend on the type of treatment, its dosage and its duration, at present it is still not possible to predict spermatogenesis recovery after treatment in specific patients. 1, 2 With the increasing availability of assisted reproductive technology (ART), many of these patients and their clinicians are seeking to preserve their fertility potential by sperm cryopreservation before embarking on gonadotoxic therapies. Application of intracytoplasmic sperm injection (ICSI) also allows many affected patients with poor
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semen characteristics or low sperm survival after thawing to father their own genetic children in the future. 2 Sperm cryopreservation is a simple and effective way of preserving their fertility potential and should be recommended for all men undergoing potentially sterilising treatments. [1] [2] [3] [4] However, the rate of sperm cryopreservation under these circumstances is low, especially in the Chinese population, 5 Moreover, data currently available about sperm cryopreservation in this population are limited. We therefore opted to perform a retrospective review of sperm cryopreservation in the Assisted Reproductive Technology Unit to explore the current situation in our locality.
Methods
Since 1995, the Prince of Wales Hospital (affiliated with the Chinese University of Hong Kong) has been providing sperm cryopreservation for male patients undergoing gonadotoxic treatment for malignant cancers that could jeopardise their fertility potential. This was therefore a retrospective study evaluating all Chinese male patients having sperm cryopreservation before proceeding to gonadotoxic treatment in our infertility centre from January 1995 to January 2012.
Before signing a written consent for cryopreservation, all relevant patients were counselled by an infertility specialist and fully informed about the procedure, including the process entailed, costs, future use, and storage duration. All the patients were screened for sexually transmitted diseases, including human immunodeficiency virus, and hepatitis B and C viruses. The maximum storage period was until the patient reached an age of 55 years or for 10 years, whichever was longer. Moreover, it was stipulated that the stored gametes were only used for a married couple, and only when the disease was in remission. Moreover, no posthumous conception would be allowed. The aforementioned stipulations were in line with the Code of Practice formulated by the Council on Human Reproductive Technology of Hong Kong since 2007. 6 In our centre, consent was renewed every 2 years.
Patients were asked to submit semen samples for cryopreservation and semen analysis by masturbation, which was performed according to the World Health Organization guidelines valid at that time. Sperm cryopreservation was performed according to a standardised protocol in our hospital, and only on semen samples containing motile spermatozoa. If no motile sperms were detected, the finding was discussed with the patient and the sample was not cryopreserved. The semen samples were mixed with an equal volume of commercially available cryoprotectant. After thorough mixing and aliquoting into cryopreservation vials, the samples were cooled by suspension in vapour-phase nitrogen at a rate of approximately -10°C per minute for 30 minutes and plunged into liquid nitrogen for storage.
The medical notes of these patients were reviewed and demographic and other data were logged. Such data included the age at diagnosis and referral, type of cancer and treatment, pre-and post-sperm cryopreservation semen analysis results, length of semen cryopreservation, results and types of ART tried. The reasons for discarding any semen samples were also explored.
Statistical analyses
The Statistical Package for the Social Sciences (Windows version 18.0; SPSS Inc, Chicago [IL], US) was used for data entry and analysis. The Chi squared test was used for categorical data and Student's t test for continuous variables. Any P<0.05 was considered statistically significant.
Results
A total of 130 male Chinese patients were referred for sperm cryopreservation in our hospital during the period January 1995 to January 2012. The mean waiting time for first consultation was 4 days with a median of 2 days. Most of the patients (94%, n=122) were referred from other departments in the public sector, while the remainder were referred from the private sector. Table 1 shows the demographic and clinical characteristics of the patients. Of the 130 patients, five did not undergo sperm cryopreservation after counselling by our specialist (3 proceeded to gonadotoxic treatment immediately and 2 declined such therapy due to their poor prognosis). Of the remaining 125 men, 122 were able to produce semen by masturbation but three did not. Regarding the 122 patients who produced semen, 10% (12/122) were diagnosed to have azoospermia based on semen analysis: seven had testicular cancer and had undergone unilateral orchidectomy, three had untreated leukaemia, and two had Hodgkin's disease with prior chemotherapy (both had received the ABVD regimen-adriamycin, bleomycin, vinblastine and dacarbazine). Thus, there were 110 men who proceeded to sperm cryopreservation.
Throughout the study period, 176 samples were cryopreserved, ranging from 1 to 5 samples per patient. Excluding the 12 samples that were azoospermic, there were 164 samples available for detailed analysis. The median semen parameters for the cryopreserved sperm were as follows: volume 2.5 (range, 0-3) mL, sperm count 35 (range, 0-170) million/mL, and motility 36% (range, 0-70%). There were no significant differences in semen parameters in patients with different cancer types.
Cryopreserved samples of 41 patients were discarded during the time of the study. They included 23 recovered patients with restored spermatogenesis according to semen analysis, 15 who died before using their sperm, two who declined to continue storing their sperm due to social problems, and one following a spontaneous pregnancy in his partner. Among the 23 recovered patients with normal semen analysis, 13 had undergone chemotherapy, six had had radiotherapy, and four had had both treatments. The mean time span between treatment and sperm disposal was 4 (range, 3-13; median, 4) years, while the mean time span from cryopreservation to death (n=15) was 3 (range, 1-13; median, 2) years. Eleven patients (32%, n=11/34) with normal semen analysis before treatment came back to consider disposal of their sperms after their treatment. However, they changed their minds as they were found to have significantly inferior semen when it was re-analysed; seven of them had counts of <15 million/mL and four patients became azoospermic. The details of these patients are listed in Table 2 .
Four patients came back to use their cryopreserved sperm for in-vitro fertilisation (IVF) with ICSI and in three of them successful singleton live births were achieved. The mean time from cryopreservation to usage was 5 years. Details of these cases are listed in Table 3 .
Discussion
With the improved survival of male cancer patients, many want to father their own child after remission.
Elective sperm cryopreservation is a simple and effective option for these patients to father their own genetic children in a timely manner. [1] [2] [3] [4] To date, there are limited data available on the current situation with regard to sperm cryopreservation for local male cancer patients. Although our study was limited in being retrospective, it is the first to report the rate of cryopreserved sperm utilisation and ART outcomes in a cohort of cancer patients from an ART unit in Hong Kong. In our cohort, up to 90% (n=110/122) of the patients were able to produce semen by masturbation and had motile sperm for cryopreservation, demonstrating the feasibility of After being diagnosed, every effort should be made to refer these patients for sperm cryopreservation before proceeding to treatment. In our study, up to 10% (n=12/122) of them were already azoospermic before sperm cryopreservation and cancer treatment, and about 32% (n=11/34) endured deterioration of their semen when it was reanalysed post-treatment. This concurs with previous studies in which a significant percentage of patients diagnosed with cancer may in fact be azoospermic before gonadotoxic treatment, presumably due to spermatogenic depression related to the cancer and that a proportion of them also become azoospermic after gonadotoxic treatment. 7 Since it is still not possible to predict which group of patients will have recovery of spermatogenesis after treatment, timely referral for sperm cryopreservation is of paramount importance.
The number of male patients being referred for sperm cryopreservation has been progressively increasing in the last few years. In our unit, the number has risen 10-fold from 2 cases per year in 1995 to 20 cases per year in 2005. However, awareness of this procedure is still insufficient. Over the past 17 years, the majority of our patients were referred by urologists, and remarkably over this period only 66 patients with testicular cancers were referred to us. This suggests a high degree of underutilisation of our service. Only a small portion of those suffering from haematological or other malignancies who receive gonadotoxic treatment were referred for sperm cryopreservation. In previous studies, this has been attributed to the lack of knowledge about ART and sperm cryopreservation. 8, 9 In a future study, we hope to elucidate the rationale and referral selection criteria used by physicians and oncologists with respect to sperm cryopreservation in male cancer patients.
We believe that financial considerations may also be a factor affecting sperm cryopreservation. In our unit, since July 2012 sperm cryopreservation has been carried out as a private service and costs around HK$4800 for every 2 years over the initial 4 years and HK$9600 for every 2 years thereafter. This compares to HK$2000 for every 2 years during the 1990s. This may be a heavy burden for low-income patients who already need to pay for their cancer treatments. Thus, for patients without existing offspring, the government should consider offering financial support for semen cryopreservation.
Moreover, many may not be aware of the improved success rate and ART outcomes from sperm cryopreservation. The literature records at least two successful live births by intrauterine insemination with sperm cryopreserved up to 28 years, exemplifying the success of this service. 10 Furthermore, the success rates of IVF and ICSI treatments using cryopreserved semen are now comparable to those of using fresh semen. 11, 12 In our study, three out of four men who came back to use their cryopreserved sperm were able to achieve a successful pregnancy, even in that one patient who only had a few motile sperms per slide. With the advance of ICSI treatment, male patients should be made aware that only a few motile spermatozoa are required to achieve fatherhood, and thus they should be encouraged to consider sperm cryopreservation even if their sperm quality is suboptimal before gonadotoxic treatment.
At the time of the study, only four men (4%, n=4/110) returned to use their cryopreserved sperm for infertility treatment. This usage rate is considered to be low compared with those reported from other international oncology-infertility centres where they ranged from 6 to 39%. [1] [2] [3] [4] [5] 12, 13 These men might never have fathered their own child had they not had cryopreserved sperm. The low usage rate in our series may have been due to the fact that many patients were still young and single at the time of sperm cryopreservation, and may not consider family planning until they are married. With the increasing trend towards late marriages in Hong Kong, family planning may be further delayed. In addition, many of these patients may still have been under surveillance for their disease during the study period and may not return until their condition is in remission or if they are certain about their long-term prognosis. Again, financial considerations and lack of awareness of the success of ART may be other factors affecting the usage. Nonetheless, we strongly believe that sperm cryopreservation should still be continued, even if only a few patients come back for treatment.
Survival from childhood malignancies in prepubertal boys is also improving due to improvements in diagnostic and treatment modalities. However, preserving fertility potential in such boys remains challenging. Sperm cryopreservation can nevertheless be performed in adolescents, if sperm can be collected by masturbation, penile vibrostimulation, or electroejaculation. 14, 15 In patients for whom sperm collection is not feasible, testicular tissue recovery and cryopreservation followed by subsequent spermatogonial stem cell transplantation may be an option but is still experimental at this stage.
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Conclusion
Sperm cryopreservation is considered an invaluable tool for preserving the progenitive potential of male patients undergoing gonadotoxic treatment. We hope this study can increase the awareness and confidence of the physicians and patients about sperm cryopreservation, so that timely referral can be made before gonadotoxic treatment.
